$INO
INOVIO PHARMACEUTICALS, INC. Stock $ino

$ino Overview Financials Valuation SEC Filings Company Website

2016 Q2 Form 10-Q Financial Statement

#000105572616000062 Filed on August 08, 2016

Income Statement

Concept	2016 Q2	2015 Q2
Revenue	$6.204M	$5.287M
YoY Change	17.35%	39.06%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$5.800M	$4.720M
YoY Change	22.88%	8.51%
% of Gross Profit
Research & Development	$19.63M	$16.69M
YoY Change	17.63%	73.71%
% of Gross Profit
Depreciation & Amortization	$790.0K	$460.0K
YoY Change	71.74%	27.78%
% of Gross Profit
Operating Expenses	$24.43M	$20.41M
YoY Change	19.72%	46.24%
Operating Profit	-$18.23M	-$15.12M
YoY Change	20.55%	48.92%
Interest Expense	-$480.0K	$8.960M
YoY Change	-105.36%	-1700.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$18.70M	-$6.162M
YoY Change	203.53%	-42.52%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$18.70M	-$6.248M
YoY Change	199.36%	-41.67%
Net Earnings / Revenue	-301.5%	-118.19%
Basic Earnings Per Share	-$0.26	-$0.09
Diluted Earnings Per Share	-$0.26	-$0.09
COMMON SHARES
Basic Shares Outstanding	72.96M shares	67.66M shares
Diluted Shares Outstanding	72.96M shares	67.84M shares

Balance Sheet

Concept	2016 Q2	2015 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$134.5M	$154.6M
YoY Change	-13.0%	41.97%
Cash & Equivalents	$28.45M	$70.30M
Short-Term Investments	$106.1M	$84.30M
Other Short-Term Assets	$3.100M	$1.900M
YoY Change	63.16%	58.33%
Inventory
Prepaid Expenses
Receivables	$10.37M	$5.609M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$148.0M	$162.1M
YoY Change	-8.74%	43.56%
LONG-TERM ASSETS
Property, Plant & Equipment	$8.701M	$5.497M
YoY Change	58.27%	20.83%
Goodwill	$10.51M	$10.11M
YoY Change	3.96%	0.0%
Intangibles	$8.449M	$4.333M
YoY Change	94.98%	-17.32%
Long-Term Investments	$5.300M	$0.00
YoY Change
Other Assets	$1.326M	$581.3K
YoY Change	128.15%	17.82%
Total Long-Term Assets	$56.02M	$39.56M
YoY Change	41.59%	35.44%
TOTAL ASSETS
Total Short-Term Assets	$148.0M	$162.1M
Total Long-Term Assets	$56.02M	$39.56M
Total Assets	$204.0M	$201.7M
YoY Change	1.13%	41.89%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$13.30M	$9.500M
YoY Change	40.0%	58.33%
Accrued Expenses	$5.006M	$2.546M
YoY Change	96.6%	48.16%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$35.49M	$14.52M
YoY Change	144.46%	25.13%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$6.200M	$5.700M
YoY Change	8.77%	-29.63%
Total Long-Term Liabilities	$6.200M	$5.700M
YoY Change	8.77%	-29.63%
TOTAL LIABILITIES
Total Short-Term Liabilities	$35.49M	$14.52M
Total Long-Term Liabilities	$6.200M	$5.700M
Total Liabilities	$41.90M	$20.75M
YoY Change	101.95%	4.33%
SHAREHOLDERS EQUITY
Retained Earnings	-$387.8M	-$348.7M
YoY Change	11.21%	9.9%
Common Stock	$73.48K	$71.81K
YoY Change	2.33%	19.05%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$162.0M	$180.6M
YoY Change
Total Liabilities & Shareholders Equity	$204.0M	$201.7M
YoY Change	1.13%	41.89%

Cashflow Statement

Concept	2016 Q2	2015 Q2
OPERATING ACTIVITIES
Net Income	-$18.70M	-$6.248M
YoY Change	199.36%	-41.67%
Depreciation, Depletion And Amortization	$790.0K	$460.0K
YoY Change	71.74%	27.78%
Cash From Operating Activities	-$13.27M	-$9.020M
YoY Change	47.12%	10.67%
INVESTING ACTIVITIES
Capital Expenditures	-$2.720M	-$640.0K
YoY Change	325.0%	-9.86%
Acquisitions
YoY Change
Other Investing Activities	$340.0K	-$28.65M
YoY Change	-101.19%	1151.09%
Cash From Investing Activities	-$2.380M	-$29.29M
YoY Change	-91.87%	879.6%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$1.300M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	2.480M	82.47M
YoY Change	-96.99%	8962.64%
NET CHANGE
Cash From Operating Activities	-13.27M	-9.020M
Cash From Investing Activities	-2.380M	-29.29M
Cash From Financing Activities	2.480M	82.47M
Net Change In Cash	-13.17M	44.16M
YoY Change	-129.82%	-531.67%
FREE CASH FLOW
Cash From Operating Activities	-$13.27M	-$9.020M
Capital Expenditures	-$2.720M	-$640.0K
Free Cash Flow	-$10.55M	-$8.380M
YoY Change	25.89%	12.63%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
	dei	Document Period End Date DocumentPeriodEndDate	2016-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001055726
CY2016Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	73548342	shares
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	INOVIO PHARMACEUTICALS, INC.
CY2015Q2	ino	Adjustmentfor Changein Fair Valueof Warrant Liability AdjustmentforChangeinFairValueofWarrantLiability	-22727	USD
	ino	Adjustmentfor Changein Fair Valueof Warrant Liability AdjustmentforChangeinFairValueofWarrantLiability	-312500	USD
CY2016Q2	ino	Adjustmentfor Changein Fair Valueof Warrant Liability AdjustmentforChangeinFairValueofWarrantLiability	0	USD
	ino	Adjustmentfor Changein Fair Valueof Warrant Liability AdjustmentforChangeinFairValueofWarrantLiability	0	USD
CY2016Q2	ino	Available For Sale Securities Ownership Percentage AvailableForSaleSecuritiesOwnershipPercentage	0.169
CY2015Q2	ino	Change In Fair Value Of Common Stock Warrants ChangeInFairValueOfCommonStockWarrants	-49773	USD
	ino	Change In Fair Value Of Common Stock Warrants ChangeInFairValueOfCommonStockWarrants	-51000	USD
CY2016Q2	ino	Change In Fair Value Of Common Stock Warrants ChangeInFairValueOfCommonStockWarrants	-113775	USD
	ino	Change In Fair Value Of Common Stock Warrants ChangeInFairValueOfCommonStockWarrants	-520024	USD
	ino	Change In Value Of Common Stock Warrants ChangeInValueOfCommonStockWarrants	51000	USD
	ino	Change In Value Of Common Stock Warrants ChangeInValueOfCommonStockWarrants	520025	USD
CY2015Q2	ino	Change In Value Of Investments In Affiliated Company ChangeInValueOfInvestmentsInAffiliatedCompany	8861145	USD
	ino	Change In Value Of Investments In Affiliated Company ChangeInValueOfInvestmentsInAffiliatedCompany	6508836	USD
CY2016Q2	ino	Change In Value Of Investments In Affiliated Company ChangeInValueOfInvestmentsInAffiliatedCompany	-705527	USD
	ino	Change In Value Of Investments In Affiliated Company ChangeInValueOfInvestmentsInAffiliatedCompany	6775450	USD
	ino	Common Stock Issued For Intangible And Other Assets CommonStockIssuedForIntangibleAndOtherAssets	0	USD
	ino	Common Stock Issued For Intangible And Other Assets CommonStockIssuedForIntangibleAndOtherAssets	4300000	USD
CY2015Q4	ino	Deferred Revenue From Affiliated Entity Current DeferredRevenueFromAffiliatedEntityCurrent	504442	USD
CY2016Q2	ino	Deferred Revenue From Affiliated Entity Current DeferredRevenueFromAffiliatedEntityCurrent	469792	USD
CY2015Q4	ino	Deferred Revenue From Affiliated Entity Noncurrent DeferredRevenueFromAffiliatedEntityNoncurrent	677371	USD
CY2016Q2	ino	Deferred Revenue From Affiliated Entity Noncurrent DeferredRevenueFromAffiliatedEntityNoncurrent	274194	USD
CY2015Q2	ino	Future Paymentstobe Receivedfrom Saleof Intangible Assets FuturePaymentstobeReceivedfromSaleofIntangibleAssets	1000000	USD
CY2015Q4	ino	Goodwill And Intangible Assets Gross GoodwillAndIntangibleAssetsGross	29731244	USD
CY2016Q2	ino	Goodwill And Intangible Assets Gross GoodwillAndIntangibleAssetsGross	35231244	USD
CY2015Q4	ino	Goodwill And Intangible Assets Net GoodwillAndIntangibleAssetsNet	14019231	USD
CY2016Q2	ino	Goodwill And Intangible Assets Net GoodwillAndIntangibleAssetsNet	18962677	USD
	ino	Increase Decrease In Deferred Revenue From Related Parties IncreaseDecreaseInDeferredRevenueFromRelatedParties	-150000	USD
	ino	Increase Decrease In Deferred Revenue From Related Parties IncreaseDecreaseInDeferredRevenueFromRelatedParties	-437827	USD
	ino	Increase Decrease In Prepaid Expenses And Other Current Assets From Affiliated Entity IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity	-337005	USD
	ino	Increase Decrease In Prepaid Expenses And Other Current Assets From Affiliated Entity IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity	1271605	USD
	ino	Interest Income Accrued On Short Term Investments Certificates Of Deposit InterestIncomeAccruedOnShortTermInvestmentsCertificatesOfDeposit	154655	USD
	ino	Interest Income Accrued On Short Term Investments Certificates Of Deposit InterestIncomeAccruedOnShortTermInvestmentsCertificatesOfDeposit	139659	USD
CY2015Q2	ino	License Fee And Milestone Revenue From Affiliated Entity LicenseFeeAndMilestoneRevenueFromAffiliatedEntity	166667	USD
	ino	License Fee And Milestone Revenue From Affiliated Entity LicenseFeeAndMilestoneRevenueFromAffiliatedEntity	279167	USD
CY2016Q2	ino	License Fee And Milestone Revenue From Affiliated Entity LicenseFeeAndMilestoneRevenueFromAffiliatedEntity	499720	USD
	ino	License Fee And Milestone Revenue From Affiliated Entity LicenseFeeAndMilestoneRevenueFromAffiliatedEntity	636720	USD
CY2015Q2	ino	Maximum Amountof Additional Equity Fundraising MaximumAmountofAdditionalEquityFundraising	10000000	USD
CY2016Q2	ino	Operating Leases Future Minimum Payments Due In Six Years OperatingLeasesFutureMinimumPaymentsDueInSixYears	9762000	USD
CY2015Q2	ino	Other Comprehensive Income Loss Unrealized Gain Loss On Investment In Affiliated Entity Net Of Tax OtherComprehensiveIncomeLossUnrealizedGainLossOnInvestmentInAffiliatedEntityNetOfTax	0	USD
	ino	Other Comprehensive Income Loss Unrealized Gain Loss On Investment In Affiliated Entity Net Of Tax OtherComprehensiveIncomeLossUnrealizedGainLossOnInvestmentInAffiliatedEntityNetOfTax	0	USD
CY2016Q2	ino	Other Comprehensive Income Loss Unrealized Gain Loss On Investment In Affiliated Entity Net Of Tax OtherComprehensiveIncomeLossUnrealizedGainLossOnInvestmentInAffiliatedEntityNetOfTax	282572	USD
	ino	Other Comprehensive Income Loss Unrealized Gain Loss On Investment In Affiliated Entity Net Of Tax OtherComprehensiveIncomeLossUnrealizedGainLossOnInvestmentInAffiliatedEntityNetOfTax	263575	USD
CY2015Q4	ino	Prepaid Expenses And Other Current Assets From Affiliated Entity PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity	610652	USD
CY2016Q2	ino	Prepaid Expenses And Other Current Assets From Affiliated Entity PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity	1882257	USD
CY2016Q2	ino	Receivablefromsaleof Intangible Assets ReceivablefromsaleofIntangibleAssets	1000000	USD
	ino	Share Based Compensation Arrangement By Share Based Payment Award Maximum Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm	P10Y
	ino	Sharebased Compensation Arrangementby Sharebased Payment Award Numberof Plans SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofPlans	2	plan
CY2016Q2	ino	Stock Sales Agreement Agent Fee StockSalesAgreementAgentFee	0.02
CY2016Q2	ino	Stock Sales Agreement Maximum Authorized Amount StockSalesAgreementMaximumAuthorizedAmount	50000000.0	USD
CY2015Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	13064899	USD
CY2016Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	12707754	USD
CY2015Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	7333059	USD
CY2016Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	10365950	USD
CY2015Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2600483	USD
CY2016Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5006287	USD
CY2015Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	2708339	USD
CY2016Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	3514362	USD
CY2015Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	534004564	USD
CY2016Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	546251246	USD
CY2015Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	219000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	442615	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	443000	USD
CY2016Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	347000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	557000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	556554	USD
CY2015Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6853635	shares
CY2016Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7736360	shares
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	2405804	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	106774	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	655334	USD
	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Aggregate Losses AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses	18000	USD
CY2016Q2	us-gaap	Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions1 AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1	41	investment
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Assets Assets	213840859	USD
CY2016Q2	us-gaap	Assets Assets	203985449	USD
CY2015Q4	us-gaap	Assets Current AssetsCurrent	171850938	USD
CY2016Q2	us-gaap	Assets Current AssetsCurrent	147969611	USD
CY2015Q3	us-gaap	Available For Sale Equity Securities Amortized Cost Basis AvailableForSaleEquitySecuritiesAmortizedCostBasis	0	USD
CY2015Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	110403192	USD
CY2016Q2	us-gaap	Available For Sale Securities AvailableForSaleSecurities	111392477	USD
CY2015Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	5046350	USD
CY2016Q2	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	5650349	USD
CY2015Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	240243	USD
CY2016Q2	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	38221	USD
CY2015Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	105597085	USD
CY2016Q2	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	105780349	USD
CY2016Q2	us-gaap	Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Greater Than Or Equal To One Year AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear	23	investment
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	190109	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	-110136	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	40543982	USD
CY2015Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	70297574	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	57632693	USD
CY2016Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	28450373	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	29753592	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-29182320	USD
CY2015Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	560904	shares
CY2016Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	284091	shares
CY2016Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	600000000	shares
CY2016Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	73482859	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	72217965	shares
CY2016Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	73482859	shares
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	72218	USD
CY2016Q2	us-gaap	Common Stock Value CommonStockValue	73483	USD
CY2015Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6380920	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-16902831	USD
CY2016Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-18099372	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-25941508	USD
CY2015Q2	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	85861	USD
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	84769	USD
CY2016Q2	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	0	USD
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	0	USD
CY2015Q2	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-6295059	USD
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-16818062	USD
CY2016Q2	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-18099372	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-246675	USD
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-25941508	USD
CY2015Q4	us-gaap	Cost Method Investments Fair Value Disclosure CostMethodInvestmentsFairValueDisclosure	5045915	USD
CY2016Q2	us-gaap	Cost Method Investments Fair Value Disclosure CostMethodInvestmentsFairValueDisclosure	5309488	USD
CY2015Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	380629	USD
CY2016Q2	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	391913	USD
CY2015Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	5485313	USD
CY2016Q2	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	5576953	USD
CY2015Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	13449768	USD
CY2016Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	14502626	USD
CY2015Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	103074	USD
CY2016Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	374043	USD
CY2015Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	175642	USD
CY2016Q2	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	175642	USD
	us-gaap	Depreciation Depreciation	451386	USD
	us-gaap	Depreciation Depreciation	827327	USD
CY2015Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	165047	USD
CY2016Q2	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	600969	USD
CY2015Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.09
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.26
CY2016Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.26
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.37
CY2015Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.09
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.27
CY2016Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.26
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.37
CY2016Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	7800000	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y1M0D
CY2015Q2	us-gaap	Equity Method Investment Ownership Percentage EquityMethodInvestmentOwnershipPercentage	0.2
CY2016Q2	us-gaap	Equity Method Investments EquityMethodInvestments	5300000	USD
CY2014Q2	us-gaap	Equity Method Investments EquityMethodInvestments	0	USD
	us-gaap	Fair Value Assumptions Expected Dividend Payments FairValueAssumptionsExpectedDividendPayments	0
	us-gaap	Fair Value Assumptions Expected Term FairValueAssumptionsExpectedTerm	P2Y2M15D
	us-gaap	Fair Value Assumptions Expected Volatility Rate FairValueAssumptionsExpectedVolatilityRate	0.63
	us-gaap	Fair Value Assumptions Risk Free Interest Rate FairValueAssumptionsRiskFreeInterestRate	0.0058
CY2015Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	23000	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	313000	USD
CY2016Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	108000	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	514000	USD
CY2015Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	15712013	USD
CY2016Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	16268567	USD
CY2016Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	3100000	USD
CY2016Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	821000	USD
CY2016Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	547000	USD
CY2016Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	1100000	USD
CY2016Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	1300000	USD
CY2016Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	1600000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	270785	USD
CY2015Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	19617873	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-2895227	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	1323827	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3032891	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	539055	USD
CY2016Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	24717873	USD
CY2015Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3905860	USD
CY2016Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	8449306	USD
CY2015Q2	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	1000000	USD
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	1000000	USD
CY2016Q2	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	1000000	USD
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	1000000	USD
	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	1000000	USD
	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	1000000	USD
CY2015Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4718260	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8826188	USD
CY2016Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5799530	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11171143	USD
CY2015Q4	us-gaap	Goodwill Goodwill	10113371	USD
CY2016Q2	us-gaap	Goodwill Goodwill	10513371	USD
CY2015Q4	us-gaap	Goodwill Gross GoodwillGross	10113371	USD
CY2016Q2	us-gaap	Goodwill Gross GoodwillGross	10513371	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-505047	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-247009	USD
	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	3388610	USD
	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	435922	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2804638	USD
CY2015Q2	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	182763	shares
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	177995	shares
CY2016Q2	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
CY2015Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3905860	USD
CY2016Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	8449306	USD
CY2015Q2	us-gaap	Interest And Other Income InterestAndOtherIncome	146332	USD
	us-gaap	Interest And Other Income InterestAndOtherIncome	284608	USD
CY2016Q2	us-gaap	Interest And Other Income InterestAndOtherIncome	341131	USD
	us-gaap	Interest And Other Income InterestAndOtherIncome	674201	USD
CY2015Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	14941277	USD
CY2016Q2	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	21716728	USD
CY2015Q2	us-gaap	Lease Incentive Receivable LeaseIncentiveReceivable	0	USD
CY2016Q2	us-gaap	Lease Incentive Receivable LeaseIncentiveReceivable	134500	USD
CY2015Q4	us-gaap	Liabilities Liabilities	37907806	USD
CY2016Q2	us-gaap	Liabilities Liabilities	41895516	USD
	us-gaap	Licenses Revenue LicensesRevenue	3686845	USD
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	213840859	USD
CY2016Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	203985449	USD
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	31466406	USD
CY2016Q2	us-gaap	Liabilities Current LiabilitiesCurrent	35494684	USD
CY2015Q2	us-gaap	Licenses Revenue LicensesRevenue	4335236	USD
	us-gaap	Licenses Revenue LicensesRevenue	8580807	USD
CY2016Q2	us-gaap	Licenses Revenue LicensesRevenue	1889988	USD
CY2015Q4	us-gaap	Minority Interest MinorityInterest	245828	USD
CY2016Q2	us-gaap	Minority Interest MinorityInterest	96269	USD
CY2015Q4	us-gaap	Minority Interest Ownership Percentage By Noncontrolling Owners MinorityInterestOwnershipPercentageByNoncontrollingOwners	0.15
CY2016Q2	us-gaap	Minority Interest Ownership Percentage By Noncontrolling Owners MinorityInterestOwnershipPercentageByNoncontrollingOwners	0.15
CY2015Q2	us-gaap	Minority Interest Ownership Percentage By Parent MinorityInterestOwnershipPercentageByParent	0.91
CY2014Q2	us-gaap	Minority Interest Ownership Percentage By Parent MinorityInterestOwnershipPercentageByParent	0.85
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	82465042	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2547222	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-31621511	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2719611	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-21089939	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-29009931	USD
	us-gaap	Proceeds From Sale Of Intangible Assets ProceedsFromSaleOfIntangibleAssets	1000000	USD
CY2015Q2	us-gaap	Net Income Loss NetIncomeLoss	-6248250	USD
	us-gaap	Net Income Loss NetIncomeLoss	-16830029	USD
CY2016Q2	us-gaap	Net Income Loss NetIncomeLoss	-18704711	USD
	us-gaap	Net Income Loss NetIncomeLoss	-26747531	USD
CY2015Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	85861	USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	84769	USD
CY2016Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	0	USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	0	USD
CY2015Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6270977	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-17142529	USD
CY2016Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-18704711	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-26747531	USD
CY2015Q2	us-gaap	Operating Expenses OperatingExpenses	20406771	USD
	us-gaap	Operating Expenses OperatingExpenses	33941019	USD
CY2016Q2	us-gaap	Operating Expenses OperatingExpenses	24430331	USD
	us-gaap	Operating Expenses OperatingExpenses	47991104	USD
CY2015Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-15120093	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-23487704	USD
CY2016Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-18226540	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-33677158	USD
CY2016Q2	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	17823000	USD
CY2016Q2	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	1939000	USD
CY2016Q2	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	1897000	USD
CY2016Q2	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	1668000	USD
CY2016Q2	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	1696000	USD
CY2016Q2	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	861000	USD
CY2015Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	676803	USD
CY2016Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1326317	USD
CY2015Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-132670	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-72802	USD
CY2016Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	322767	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	542448	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	1200000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1173024	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2196896	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	35193487	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	27985410	USD
	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	0	USD
	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	149559	USD
CY2015Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	917257	USD
CY2016Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1188042	USD
CY2015Q2	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	81900000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	81902363	USD
CY2016Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1300000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1301435	USD
	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	3745000	USD
	us-gaap	Proceeds From Sale Of Intangible Assets ProceedsFromSaleOfIntangibleAssets	1000000	USD
CY2016Q2	us-gaap	Profit Loss ProfitLoss	-18704711	USD
	us-gaap	Profit Loss ProfitLoss	-26747531	USD
CY2016Q2	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	11.12
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.47
	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	27662695	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	562679	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1395346	USD
CY2015Q2	us-gaap	Profit Loss ProfitLoss	-6162389	USD
	us-gaap	Profit Loss ProfitLoss	-16745260	USD
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7306695	USD
CY2016Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8700628	USD
CY2015Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16688511	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	26114831	USD
CY2016Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	19630801	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	37819961	USD
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-361097896	USD
CY2016Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-387845427	USD
CY2015Q2	us-gaap	Revenue From Grants RevenueFromGrants	784775	USD
	us-gaap	Revenue From Grants RevenueFromGrants	1593341	USD
CY2016Q2	us-gaap	Revenue From Grants RevenueFromGrants	3814083	USD
	us-gaap	Revenue From Grants RevenueFromGrants	9990381	USD
CY2015Q2	us-gaap	Revenues Revenues	5286678	USD
	us-gaap	Revenues Revenues	10453315	USD
CY2016Q2	us-gaap	Revenues Revenues	6203791	USD
	us-gaap	Revenues Revenues	14313946	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	3773134	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	5251166	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P3Y
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.02
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.62
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	6.07
CY2015Q2	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	8.00
CY2015Q4	us-gaap	Short Term Investments ShortTermInvestments	105357277	USD
CY2016Q2	us-gaap	Short Term Investments ShortTermInvestments	106082989	USD
CY2015Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	10925000	shares
CY2016Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	119400	shares
	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	119400.0	shares
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	175687225	USD
CY2016Q2	us-gaap	Stockholders Equity StockholdersEquity	161993664	USD
CY2015Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	175933053	USD
CY2016Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	162089933	USD
	us-gaap	Straight Line Rent StraightLineRent	-241708	USD
	us-gaap	Straight Line Rent StraightLineRent	31783	USD
CY2016Q2	us-gaap	Tenant Improvements TenantImprovements	1100000	USD
CY2015Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	1301138	USD
CY2016Q2	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	1815343	USD
CY2015Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	67838738	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	64376523	shares
CY2016Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	72957159	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	72591986	shares
CY2015Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	67655975	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	64198528	shares
CY2016Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	72957159	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	72591986	shares
	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Organization and Operations</font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> Inovio Pharmaceuticals, Inc. (the “Company” or “Inovio”), a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases.  Inovio’s synthetic products are based on the Company’s SynCon</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> design.  The Company has completed, current or planned clinical programs of its proprietary SynCon</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> products for HPV-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), HIV, Ebola, Middle East Respiratory Syndrome (MERS) and Zika virus.  The Company's partners and collaborators include MedImmune, LLC, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (“Roche”), The Wistar Institute, University of Pennsylvania, GeneOne Life Science Inc. ("GeneOne"), Drexel University, National Microbiology Laboratory of the Public Health Agency of Canada, National Institute of Allergy and Infectious Diseases (“NIAID”), United States Military HIV Research Program (“USMHRP”), U.S. Army Medical Research Institute of Infectious Diseases (“USAMRIID”), HIV Vaccines Trial Network (“HVTN”),  and Defense Advanced Research Projects Agency (“DARPA”). Inovio is incorporated in Delaware.</font></div></div>

Files In Submission

Name	View Source	Status
0001055726-16-000062-index-headers.html	Edgar Link	pending
0001055726-16-000062-index.html	Edgar Link	pending
0001055726-16-000062.txt	Edgar Link	pending
0001055726-16-000062-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
ino-20160630.xml	Edgar Link	completed
ino-20160630.xsd	Edgar Link	pending
ino-20160630_cal.xml	Edgar Link	unprocessable
ino-20160630_def.xml	Edgar Link	unprocessable
ino-20160630_lab.xml	Edgar Link	unprocessable
ino-20160630_pre.xml	Edgar Link	unprocessable
ino-63016x10q.htm	Edgar Link	pending
ino-6302016x10qex311.htm	Edgar Link	pending
ino-6302016x10qex312.htm	Edgar Link	pending
ino-6302016x10qex321.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$INO
INOVIO PHARMACEUTICALS, INC. Stock $ino

2016 Q2 Form 10-Q Financial Statement

#000105572616000062 Filed on August 08, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$INO INOVIO PHARMACEUTICALS, INC. Stock $ino

2016 Q2 Form 10-Q Financial Statement

#000105572616000062 Filed on August 08, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$INO
INOVIO PHARMACEUTICALS, INC. Stock $ino